Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects, ≥18 years of age.~* Single- or double-lung transplant recipients scheduled for bronchoscopy with TBLB.~* Willingness to sign an informed consent for study participation.~Exclusion Criteria:~* Age \<18 years.~* Pregnancy.~* Inability to understand and provide a written informed consent.~Exclusion criteria for TBLB:~* Platelet count \<50 K/microL.~* International normalized ratio (INR) \>1.5.~* Known bleeding diathesis.~* Use of prophylactic or therapeutic dose of unfractionated heparin within 6 hours of the procedure.~* Use of prophylactic dose of low molecular weight heparin within 12 hours of the procedure.~* Use of therapeutic dose of low molecular weight heparin within 24 hours of the procedure.~* Use of oral direct thrombin inhibitors or oral factor 10a inhibitors within 48 hours of the procedure.~* Use of clopidogrel, ticlopidine, ticagrelor, or prasugrel within 5 days of the procedure.~* Uremia, defined as estimated glomerular filtration rate (eGFR) ≤30 mL/min.~* Moderate to severe pulmonary hypertension as defined by a mean pulmonary artery pressure of \>40 mm Hg on right heart catheterization or an estimated pulmonary artery systolic pressure of \>62 mm Hg on transthoracic echocardiography, both performed within 1 year of the procedure.~* An additional synchronous procedure with possible bleeding (bronchoalveolar lavage and endobronchial biopsy allowed).~* Decompensated liver cirrhosis, defined as the presence of clinically significant ascites, clinical evidence of esophageal or gastric varices, or history of bleeding from gastric or esophageal varices.~* Prior history of TBLB-related airway bleeding requiring admission to the hospital or advanced measures to achieve hemostasis, including endotracheal intubation, bronchial blocker application, bronchial artery embolization, or surgical intervention.~Exclusion criteria for application of topical epinephrine:~* Systolic heart failure with an ejection fraction (EF) of \<35% as assess by echocardiography performed within one year prior to the procedure.~* Myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, or coronary artery bypass surgery within 6 months prior to the procedure.~* Symptoms and/or ECG findings suggestive of ongoing cardiac ischemia on the day of the procedure.~* Moderate- to severe-grade cardiac valvulopathy as assessed by echocardiography performed within one year prior to the procedure.~* Inadequately controlled supraventricular arrhythmia, including atrial fibrillation, atrial flutter, and atrio-ventricular node re-entrant tachycardia (AVNRT) as revealed by ECG or cardiac monitoring at the time of the procedure.~* Presence of an internal cardioverter/defibrillator.~* History of second or third degree (complete) heart block or sick sinus syndrome.~* Baseline ECG or cardiac monitoring revealing frequent occurrence (≥10 events per minute) of atrial or ventricular ectopy documented prior to or at the time of the procedure.~* History of ventricular arrhythmias requiring pharmacologic or electrical cardioversion within the 2 years preceding the procedure.~* Serum potassium of \<3.0 mmol/L within the week prior to the procedure.~* Serum glucose level of ≥300 mg/dL within the week prior to the procedure.~* Any history of critical ischemia related to peripheral arterial disease.~* Persistent resting heart rate (HR) measurement of ≥120 beats per minute prior to or at the time of the procedure.~* Persistent resting systolic blood pressure (SBP) measurement of ≥180 mm Hg prior to or at the time of the procedure.~* Persistent resting diastolic blood pressure (DBP) measurement of ≥110 mm Hg prior to or at the time of the procedure.~* History of acute closed-angle glaucoma within one year of the procedure.~* Diagnosis of pheochromocytoma requiring pharmacologic therapy with an alpha adrenoreceptor blocker at the time of the procedure.~* Diagnosis of thyrotoxicosis requiring pharmacologic therapy with an anti-thyroid agent at the time of the procedure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prophylactic topical epinephrine (Type: EXPERIMENTAL): Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical epinephrine in a blinded manner prior to performance of transbronchial lung biopsy.
- Placebo (Type: PLACEBO_COMPARATOR): Study participants who meet inclusion and exclusion criteria and allocated to this arm will be randomized to receive prophylactic endobronchial topical placebo in the form of normal saline in a blinded manner prior to performance of transbronchial lung biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).